We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

21 hedge funds and large institutions have $311K invested in Celgene Corporation Contingent Value Rights in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

11% more funds holding

Funds holding: 1921 (+2)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

69% less capital invested

Capital invested by funds: $1.02M → $311K (-$707K)

Holders
21
Holders Change
+2
Holders Change %
+10.53%
% of All Funds
0.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
5
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CELGZ Hedge Fund Activity: Q1 2018 in Review

21 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q1 2018, worth a combined $311K — down 69% from $1.02M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CELGZ positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $21.3K. The largest seller was Birchview Capital, cutting an estimated $32.8K.

  • 21 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q1 2018, up from 19 in Q4 2017.
  • Funds reported $311K of Celgene Corporation Contingent Value Rights stock for Q1 2018, down 69% quarter-over-quarter.
  • 3 funds opened new Celgene Corporation Contingent Value Rights positions in Q1 2018 and 1 closed out, a net change of +2 holders.
  • The largest Celgene Corporation Contingent Value Rights buyer in Q1 2018 was Citadel Advisors, an estimated $21.3K added.
  • The largest Celgene Corporation Contingent Value Rights seller in Q1 2018 was Birchview Capital, an estimated $32.8K sold.

Based on aggregated 13F filings for Q1 2018.